Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Carl Zeiss Meditec AG    AFX   DE0005313704

CARL ZEISS MEDITEC AG

(AFX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Carl Zeiss Meditec AG : achieves strong revenue and EBIT growth in first three months 2018/19

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/15/2019 | 07:37am EDT

Carl Zeiss Meditec (ISIN: DE0005313704) has achieved revenue of approximately EUR 324 million in the first three months of fiscal year 2018/19, based on preliminary data.

This corresponds to revenue growth of around 10% vs. the previous year's value of EUR 294.7 million. Currency effects only had a minor impact on growth.

In the same period, earnings before interest and taxes (EBIT) increased significantly to EUR 48.1 million (prev. year EUR 38.9 million). This corresponds to an EBIT margin (EBIT in percent of revenue) of 14.9% (prev. year 13.2%). EBIT was positively impacted by temporarily reduced research & development expenses. For fiscal year 2018/19, the company still expects an EBIT margin between 14% to 16%.

The 3-months quarterly statement for fiscal year 2018/19 will be published on February 11, 2019.

Contact for investors and press

Sebastian Frericks

Director Investor Relations

Carl Zeiss Meditec AG

Phone: +49 3641 220-116

hinvestors.meditec@zeiss.com

Brief profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on MDAX and TecDax of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery.

With approximately 3,050 employees worldwide, the Group generated revenue of EUR1,280.9m in fiscal year 2017/18 (to 30 September).

The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CARL ZEISS MEDITEC AG
05/06GLOBAL MARKETS LIVE : Boeing, Berkshire Hathaway, Airbus, Occidental Petroleum…
05/06CARL ZEISS MEDITEC : First half year 2018/2019: Continued profitable growth for ..
PU
05/06CARL ZEISS MEDITEC : Continued profitable growth for Carl Zeiss Meditec
EQ
04/29CARL ZEISS MEDITEC : ZEISS PLEX Elite 2.0 at ARVO
AQ
04/29CARL ZEISS MEDITEC AG : Preliminary announcement of the publication of financial..
EQ
04/12European shares end higher boosted by banks and auto stocks
RE
04/12CARL ZEISS MEDITEC : reports further growth and defines expectations for fiscal ..
EQ
04/04Medical Imaging Workstations Market 2026 Trends, Top Companies - Ampronix, Ca..
AQ
03/20CARL ZEISS MEDITEC : Ex-dividend day for final dividend
FA
03/11CARL ZEISS MEDITEC : FDA Clearance for Epithelial Thickness Mapping
AQ
More news
Financials (€)
Sales 2019 1 410 M
EBIT 2019 235 M
Net income 2019 162 M
Finance 2019 658 M
Yield 2019 0,69%
P/E ratio 2019 49,86
P/E ratio 2020 42,01
EV / Sales 2019 5,15x
EV / Sales 2020 4,67x
Capitalization 7 920 M
Chart CARL ZEISS MEDITEC AG
Duration : Period :
Carl Zeiss Meditec AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARL ZEISS MEDITEC AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 80,6 €
Spread / Average Target -9,0%
EPS Revisions
Managers
NameTitle
Ludwin Monz President & Chief Executive Officer
Michael Kaschke Chairman-Supervisory Board
Justus Felix Wehmer Chief Financial Officer
Markus Guthoff Member-Supervisory Board
Cornelia Grandy Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
CARL ZEISS MEDITEC AG28.99%8 833
THERMO FISHER SCIENTIFIC17.48%105 159
DANAHER CORPORATION26.38%93 300
INTUITIVE SURGICAL0.97%55 787
BOSTON SCIENTIFIC CORPORATION5.52%51 857
ILLUMINA2.18%44 187